Adaptive Biotechnologies Corp vs Vanguard Global ex-US Real Estate Index Fd ETF — how do they compare? Adaptive Biotechnologies Corp trades at $25.41 (market cap $4.04B), while Vanguard Global ex-US Real Estate Index Fd ETF trades at $45.51. The key difference: Adaptive Biotechnologies Corp is trading nearer its 52-week high, Vanguard Global ex-US Real Estate Index Fd ETF nearer its low. Which is the better fit depends on your goals.
| ADPT | VNQI | |
|---|---|---|
Market Cap | $4.04B | — |
Sector | Health | — |
52-Week High | $25.45 | $50.76 |
52-Week Low | $12.30 | $43.26 |
Enterprise Value | $4.10B | — |
Signals from Pluang's Aura AI — not financial advice
Adaptive Biotechnologies (ADPT) trades at $25.24, near its 52-week high, with a bullish technical outlook. The company is executing a strategic separation into a pure-play MRD diagnostics business, showing strong revenue growth of 49% year-over-year in MRD and improving margins. Despite persistent net losses, cash flow turned positive in 2025, and recent earnings have mostly beaten expectations, indicating operational progress.
The outlook is cautiously optimistic, driven by the business separation potentially unlocking value and the MRD segment's growth. Key risks include sustained profitability challenges and high valuation multiples. Analyst consensus is bullish with a $25.50 price target, but investors should weigh the growth potential against the company's current lack of earnings.
VNQI (Vanguard Global ex-U.S. Real Estate ETF) trades at $45.77, up 0.46% with a bullish technical signal from moving averages. The ETF provides diversified international real estate exposure across 30+ countries outside the U.S., featuring a low expense ratio and higher dividend yield compared to domestic REIT ETFs. Recent news highlights ongoing comparisons with competing real estate funds, with VNQI's international diversification being a key differentiator.
The outlook for VNQI remains positive given its global real estate diversification benefits and income-oriented profile. Key opportunities include exposure to growing international property markets and attractive dividend yield, while risks involve currency fluctuations, geopolitical uncertainties, and potential underperformance relative to U.S. real estate markets. The ETF's low-cost structure supports long-term total return potential for investors seeking international real estate exposure.
Trailing returns across standard periods
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →The fund employs an indexing investment approach designed to track the performance of the S&P Global ex-US Property Index, a float-adjusted, market-capitalization-weighted index that measures the equity market performance of international real estate stocks in both developed and emerging markets. The index is composed of stocks of publicly traded equity real estate investment trusts (known as REITs) and certain real estate management and development companies (REMDs).
Read more on VNQI →